array(40) {
  [0]=>
  string(4) "8371"
  ["article_id"]=>
  string(4) "8371"
  [1]=>
  string(50) "Experts stress radiology preparedness for COVID-19"
  ["article_title"]=>
  string(50) "Experts stress radiology preparedness for COVID-19"
  [2]=>
  string(150) "A new article outlines priorities for handling COVID-19 cases and suggests strategies that radiology departments can implement to contain further infe"
  ["short_description"]=>
  string(150) "A new article outlines priorities for handling COVID-19 cases and suggests strategies that radiology departments can implement to contain further infe"
  [3]=>
  string(210) "A new article outlines priorities for handling COVID-19 cases and suggests strategies that radiology departments can implement to contain further infection spread and protect hospital staff and other patients. "
  ["description"]=>
  string(210) "A new article outlines priorities for handling COVID-19 cases and suggests strategies that radiology departments can implement to contain further infection spread and protect hospital staff and other patients. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316145328.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316145328.htm"
  [15]=>
  string(19) "2020-03-17 02:53:28"
  ["add_date"]=>
  string(19) "2020-03-17 02:53:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:16"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8372"
  ["article_id"]=>
  string(4) "8372"
  [1]=>
  string(82) "Coronavirus spreads quickly and sometimes before people have symptoms, study finds"
  ["article_title"]=>
  string(82) "Coronavirus spreads quickly and sometimes before people have symptoms, study finds"
  [2]=>
  string(150) "Infectious disease researchers studying the novel coronavirus were able to identify how quickly the virus can spread, a factor that may help public he"
  ["short_description"]=>
  string(150) "Infectious disease researchers studying the novel coronavirus were able to identify how quickly the virus can spread, a factor that may help public he"
  [3]=>
  string(397) "Infectious disease researchers studying the novel coronavirus were able to identify how quickly the virus can spread, a factor that may help public health officials in their efforts at containment. They found that time between cases in a chain of transmission is less than a week and that more than 10 percent of patients are infected by somebody who has the virus but does not yet have symptoms. "
  ["description"]=>
  string(397) "Infectious disease researchers studying the novel coronavirus were able to identify how quickly the virus can spread, a factor that may help public health officials in their efforts at containment. They found that time between cases in a chain of transmission is less than a week and that more than 10 percent of patients are infected by somebody who has the virus but does not yet have symptoms. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316143313.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316143313.htm"
  [15]=>
  string(19) "2020-03-17 02:33:13"
  ["add_date"]=>
  string(19) "2020-03-17 02:33:13"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:16"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8373"
  ["article_id"]=>
  string(4) "8373"
  [1]=>
  string(87) "New Yorkers and Coronavirus -- Support for school closures, while most feel not at risk"
  ["article_title"]=>
  string(87) "New Yorkers and Coronavirus -- Support for school closures, while most feel not at risk"
  [2]=>
  string(150) "A new survey released today found that 60% of New York State residents believe their chances of contracting the novel Coronavirus are low or very low."
  ["short_description"]=>
  string(150) "A new survey released today found that 60% of New York State residents believe their chances of contracting the novel Coronavirus are low or very low."
  [3]=>
  string(440) "A new survey released today found that 60% of New York State residents believe their chances of contracting the novel Coronavirus are low or very low. The survey of 1000 New York households, conducted between March 13-15, 2020 and considered accurate within a range of 3%, also found that more than half (55%) of all respondents live in households with one or more members over age 60, the highest risk age group for Coronavirus infection. "
  ["description"]=>
  string(440) "A new survey released today found that 60% of New York State residents believe their chances of contracting the novel Coronavirus are low or very low. The survey of 1000 New York households, conducted between March 13-15, 2020 and considered accurate within a range of 3%, also found that more than half (55%) of all respondents live in households with one or more members over age 60, the highest risk age group for Coronavirus infection. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316141550.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316141550.htm"
  [15]=>
  string(19) "2020-03-17 02:15:50"
  ["add_date"]=>
  string(19) "2020-03-17 02:15:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:16"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8374"
  ["article_id"]=>
  string(4) "8374"
  [1]=>
  string(83) "New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus"
  ["article_title"]=>
  string(83) "New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus"
  [2]=>
  string(150) "Researchers have developed a new kind of CRISPR screen technology to target RNA. The team leveraged their technology for a critical analysis: The COVI"
  ["short_description"]=>
  string(150) "Researchers have developed a new kind of CRISPR screen technology to target RNA. The team leveraged their technology for a critical analysis: The COVI"
  [3]=>
  string(246) "Researchers have developed a new kind of CRISPR screen technology to target RNA. The team leveraged their technology for a critical analysis: The COVID-19 public health emergency is due to a coronavirus, which contains an RNA - not DNA - genome. "
  ["description"]=>
  string(246) "Researchers have developed a new kind of CRISPR screen technology to target RNA. The team leveraged their technology for a critical analysis: The COVID-19 public health emergency is due to a coronavirus, which contains an RNA - not DNA - genome. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316141514.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316141514.htm"
  [15]=>
  string(19) "2020-03-17 02:15:14"
  ["add_date"]=>
  string(19) "2020-03-17 02:15:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:16"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8433"
  ["article_id"]=>
  string(4) "8433"
  [1]=>
  string(46) "New Tests Enter the Scene as COVID-19 Rages On"
  ["article_title"]=>
  string(46) "New Tests Enter the Scene as COVID-19 Rages On"
  [2]=>
  string(153) "&#nlTests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the l"
  ["short_description"]=>
  string(153) "&#nlTests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the l"
  [3]=>
  string(5708) "&#nl
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions.
&#nl
Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test.
&#nl
In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab. The company said the estimated time-to-result also includes time for sample preparation and instrument analysis.
&#nl
"The authorization of our diagnostic test for COVID-19 will help to protect patients and enable medical staff to respond swiftly to treat those who are ill and prevent the spread of infection,” Marc Casper, chairman, president and CEO of Thermo Fisher said in prepared remarks.
&#nl
The news comes on the heels of two significant developments from Thermo Fisher, which include the company making a bid to acquire Qiagen and entering into a companion diagnostic collaboration for non-small cell lung cancer with Janssen.
&#nl
Mayo Clinic’s said its test “Severe Acute Respiratory Syndrome (Coronavirus-2 (SARS CoV-2), Molecular Detection has been fully validated and submitted to FDA for review and EUA. Results from the test can come within 24 hours, Mayo Clinic said.
&#nl
 
&#nl
&#nl
&#nl
e40d4bd4-3a3c-4463-b598-63cd3c12b32c.jpg
&#nl
&#nl
&#nl

REUTERS / JONATHAN ERNST - stock.adobe.com
&#nl
&#nl
&#nl
&#nl
Image Credit: 
&#nl
&#nl
REUTERS / JONATHAN ERNST - stock.adobe.com
&#nl
&#nl
&#nl
&#nl
&#nl
&#nl
           
&#nl
 
&#nl
            Vice President Mike Pence speaks during a press conference detailing the next steps in combatting the spread of COVID-19. 
&#nl
 
&#nl
Latest COVID-19 Developments
&#nl
Currently, the U.S is engaging in social distancing to stop the rapidly spreading disease. There are about 3,837 people in the U.S. that have been infected by COVID-19 and 70 have died from the disease, according to Worldometer. About 73 people have recovered.
&#nl
During a Sunday news conference, the Trump Administration announced additional measures to help stem the tide of disease and said there would be drive-through testing for COVID-19. The first people allowed to use this testing will be healthcare workers and first responders and people over 65 who have symptoms consistent with the virus, according to a report from The Washington Post.
&#nl
The associated press is reporting the first patient in a trial the National Institutes of Health is funding, will receive a dose of an experimental vaccine to protect against COVID-19. The trial is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, according to the AP report. The vaccine is being co-developed by NIH and Cambridge, MA-based Moderna
&#nl
However, the AP reported Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases even if the safety tests go well it would take about a year to a year and a half for the vaccine to be used for widespread use.
&#nl
 
"
  ["description"]=>
  string(5708) "&#nl
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions.
&#nl
Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test.
&#nl
In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab. The company said the estimated time-to-result also includes time for sample preparation and instrument analysis.
&#nl
"The authorization of our diagnostic test for COVID-19 will help to protect patients and enable medical staff to respond swiftly to treat those who are ill and prevent the spread of infection,” Marc Casper, chairman, president and CEO of Thermo Fisher said in prepared remarks.
&#nl
The news comes on the heels of two significant developments from Thermo Fisher, which include the company making a bid to acquire Qiagen and entering into a companion diagnostic collaboration for non-small cell lung cancer with Janssen.
&#nl
Mayo Clinic’s said its test “Severe Acute Respiratory Syndrome (Coronavirus-2 (SARS CoV-2), Molecular Detection has been fully validated and submitted to FDA for review and EUA. Results from the test can come within 24 hours, Mayo Clinic said.
&#nl
 
&#nl
&#nl
&#nl
e40d4bd4-3a3c-4463-b598-63cd3c12b32c.jpg
&#nl
&#nl
&#nl

REUTERS / JONATHAN ERNST - stock.adobe.com
&#nl
&#nl
&#nl
&#nl
Image Credit: 
&#nl
&#nl
REUTERS / JONATHAN ERNST - stock.adobe.com
&#nl
&#nl
&#nl
&#nl
&#nl
&#nl
           
&#nl
 
&#nl
            Vice President Mike Pence speaks during a press conference detailing the next steps in combatting the spread of COVID-19. 
&#nl
 
&#nl
Latest COVID-19 Developments
&#nl
Currently, the U.S is engaging in social distancing to stop the rapidly spreading disease. There are about 3,837 people in the U.S. that have been infected by COVID-19 and 70 have died from the disease, according to Worldometer. About 73 people have recovered.
&#nl
During a Sunday news conference, the Trump Administration announced additional measures to help stem the tide of disease and said there would be drive-through testing for COVID-19. The first people allowed to use this testing will be healthcare workers and first responders and people over 65 who have symptoms consistent with the virus, according to a report from The Washington Post.
&#nl
The associated press is reporting the first patient in a trial the National Institutes of Health is funding, will receive a dose of an experimental vaccine to protect against COVID-19. The trial is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, according to the AP report. The vaccine is being co-developed by NIH and Cambridge, MA-based Moderna
&#nl
However, the AP reported Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases even if the safety tests go well it would take about a year to a year and a half for the vaccine to be used for widespread use.
&#nl
 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(70) "https://www.mddionline.com/new-tests-enter-scene-covid-19-spread-rages"
  ["blog_url"]=>
  string(70) "https://www.mddionline.com/new-tests-enter-scene-covid-19-spread-rages"
  [15]=>
  string(19) "2020-03-17 01:13:14"
  ["add_date"]=>
  string(19) "2020-03-17 01:13:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:33"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8434"
  ["article_id"]=>
  string(4) "8434"
  [1]=>
  string(44) "Can Remote Patient Monitoring Curb COVID-19?"
  ["article_title"]=>
  string(44) "Can Remote Patient Monitoring Curb COVID-19?"
  [2]=>
  string(153) "&#nlBioIntelliSense’s BioSticker wearable sensor for monitoring patient vital signs remotely could prove useful during the COVID-19 pan"
  ["short_description"]=>
  string(153) "&#nlBioIntelliSense’s BioSticker wearable sensor for monitoring patient vital signs remotely could prove useful during the COVID-19 pan"
  [3]=>
  string(4625) "&#nl
BioIntelliSense’s BioSticker wearable sensor for monitoring patient vital signs remotely could prove useful during the COVID-19 pandemic. FDA cleared early this year to continuously monitor a patient’s respiratory rate, heart rate, and skin temperature, BioSticker can now also measure the frequency of a patient's coughing, sneezing, and vomiting, Jim Mault, CEO of BioIntelliSense, told MD+DI. In addition, “the BioIntelliSense Data Service in combination with the FDA-cleared BioSticker remote monitoring device and 5G-enabled BioHub allows for continuous health data for earlier, proactive clinical interventions,” he said.
&#nl
According to guidance from the Centers for Disease Control and Prevention (CDC), the hallmark symptoms of COVID-19 include fever, coughing, and shortness of breath, Mault explained. “These are the signs our BioSticker can monitor,” he said. “A multitude of health systems are asking for initial sets of BioSticker and BioHub for testing.”
&#nl
Mault emphasized that while the “vast majority of people who get COVID-19 will be fine,” there is “a small number of very high-risk, vulnerable patients.” He describes them as patients who are 70 years and older and also have significant chronic disease, such as heart failure and emphysema. “A lot of these patients will develop pneumonia and end up in the hospital and potentially in the intensive care unit,” he said. He also included organ transplant, chemotherapy, and immunosuppressed patients in the high-risk category.
&#nl
If these vulnerable patients should become infected with COVID-19 and are in isolation, “these are the ones who are good candidates for remote monitoring to see whether they progress,” he said. “It would be prudent to actively monitor them and keep them from progressing to hospitalization and an intensive care (IC) unit. Remote patient monitoring is well suited to monitoring these patients closely, and if we see that they develop symptoms, virtual care centers can act.”
&#nl
BioSticker may also help address another potential challenge during the pandemic—overwhelmed hospitals. “The big problem for all our hospitals—they don’t have the capacity for all these incoming patients,” said Mault. COVID-19 “will consume our care areas and our IC units with people who will get hit hard.”
&#nl
Mault believes that BioSticker could help with early hospital discharge. “If someone does get admitted, we want to get to a point and capability to say—'OK, you’re getting better so let’s put a sticker on you to make sure you do get better and monitor you remotely at home.’ ”
&#nl
Such early hospital discharges would free up capacity for new admissions, he added. “We can offload patients as they are recovering from COVID-19 and send them home a day or two early with continuous monitoring at home.”
&#nl
BioSticker and BioHub are designed to be patient friendly, which could help self-isolating and self-quarantining patients apply the technology without going into a doctor’s office, he said. “There are no requirements for a healthcare professional to place BioSticker or train a patient, so it can all be done by the patient,” Mault said. “Our packaging is designed so that the product can be mailed to patients and they can place the sticker as easily as applying a Band-Aid. And BioHub automatically turns on and talks to the sticker.”
&#nl
Mault said that COVID-19 is forcing health systems to perform remote patient monitoring, which will have tremendous benefits after this pandemic has passed. “Health systems will see there are capabilities to take care of patients,” he said.
"
  ["description"]=>
  string(4625) "&#nl
BioIntelliSense’s BioSticker wearable sensor for monitoring patient vital signs remotely could prove useful during the COVID-19 pandemic. FDA cleared early this year to continuously monitor a patient’s respiratory rate, heart rate, and skin temperature, BioSticker can now also measure the frequency of a patient's coughing, sneezing, and vomiting, Jim Mault, CEO of BioIntelliSense, told MD+DI. In addition, “the BioIntelliSense Data Service in combination with the FDA-cleared BioSticker remote monitoring device and 5G-enabled BioHub allows for continuous health data for earlier, proactive clinical interventions,” he said.
&#nl
According to guidance from the Centers for Disease Control and Prevention (CDC), the hallmark symptoms of COVID-19 include fever, coughing, and shortness of breath, Mault explained. “These are the signs our BioSticker can monitor,” he said. “A multitude of health systems are asking for initial sets of BioSticker and BioHub for testing.”
&#nl
Mault emphasized that while the “vast majority of people who get COVID-19 will be fine,” there is “a small number of very high-risk, vulnerable patients.” He describes them as patients who are 70 years and older and also have significant chronic disease, such as heart failure and emphysema. “A lot of these patients will develop pneumonia and end up in the hospital and potentially in the intensive care unit,” he said. He also included organ transplant, chemotherapy, and immunosuppressed patients in the high-risk category.
&#nl
If these vulnerable patients should become infected with COVID-19 and are in isolation, “these are the ones who are good candidates for remote monitoring to see whether they progress,” he said. “It would be prudent to actively monitor them and keep them from progressing to hospitalization and an intensive care (IC) unit. Remote patient monitoring is well suited to monitoring these patients closely, and if we see that they develop symptoms, virtual care centers can act.”
&#nl
BioSticker may also help address another potential challenge during the pandemic—overwhelmed hospitals. “The big problem for all our hospitals—they don’t have the capacity for all these incoming patients,” said Mault. COVID-19 “will consume our care areas and our IC units with people who will get hit hard.”
&#nl
Mault believes that BioSticker could help with early hospital discharge. “If someone does get admitted, we want to get to a point and capability to say—'OK, you’re getting better so let’s put a sticker on you to make sure you do get better and monitor you remotely at home.’ ”
&#nl
Such early hospital discharges would free up capacity for new admissions, he added. “We can offload patients as they are recovering from COVID-19 and send them home a day or two early with continuous monitoring at home.”
&#nl
BioSticker and BioHub are designed to be patient friendly, which could help self-isolating and self-quarantining patients apply the technology without going into a doctor’s office, he said. “There are no requirements for a healthcare professional to place BioSticker or train a patient, so it can all be done by the patient,” Mault said. “Our packaging is designed so that the product can be mailed to patients and they can place the sticker as easily as applying a Band-Aid. And BioHub automatically turns on and talks to the sticker.”
&#nl
Mault said that COVID-19 is forcing health systems to perform remote patient monitoring, which will have tremendous benefits after this pandemic has passed. “Health systems will see there are capabilities to take care of patients,” he said.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(70) "https://www.mddionline.com/can-remote-patient-monitoring-curb-covid-19"
  ["blog_url"]=>
  string(70) "https://www.mddionline.com/can-remote-patient-monitoring-curb-covid-19"
  [15]=>
  string(19) "2020-03-17 00:35:35"
  ["add_date"]=>
  string(19) "2020-03-17 00:35:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:34"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8303"
  ["article_id"]=>
  string(4) "8303"
  [1]=>
  string(70) "Exercise Helps Men During Hormone Treatment for Prostate Cancer: Study"
  ["article_title"]=>
  string(70) "Exercise Helps Men During Hormone Treatment for Prostate Cancer: Study"
  [2]=>
  string(153) "MONDAY, March 16, 2020 -- Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.&#nlThe treatment -- ca"
  ["short_description"]=>
  string(153) "MONDAY, March 16, 2020 -- Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.&#nlThe treatment -- ca"
  [3]=>
  string(252) "MONDAY, March 16, 2020 -- Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.&#nlThe treatment -- called androgen suppression therapy or androgen deprivation therapy (ADT) -- uses drugs or surgery..."
  ["description"]=>
  string(252) "MONDAY, March 16, 2020 -- Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.&#nlThe treatment -- called androgen suppression therapy or androgen deprivation therapy (ADT) -- uses drugs or surgery..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(209) "https://www.drugs.com/news/exercise-helps-men-during-hormone-prostate-cancer-study-88978.html?utm_source=ddc&utm_medium=rss&utm_campaign=Exercise+Helps+Men+During+Hormone+Treatment+for+Prostate+Cancer%3A+Study"
  ["blog_url"]=>
  string(209) "https://www.drugs.com/news/exercise-helps-men-during-hormone-prostate-cancer-study-88978.html?utm_source=ddc&utm_medium=rss&utm_campaign=Exercise+Helps+Men+During+Hormone+Treatment+for+Prostate+Cancer%3A+Study"
  [15]=>
  string(19) "2020-03-17 00:03:26"
  ["add_date"]=>
  string(19) "2020-03-17 00:03:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:42"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8327"
  ["article_id"]=>
  string(4) "8327"
  [1]=>
  string(106) "Some community pharmacies on ‘brink of collapse’ following COVID-19, says pharmacy negotiator"
  ["article_title"]=>
  string(106) "Some community pharmacies on ‘brink of collapse’ following COVID-19, says pharmacy negotiator"
  [2]=>
  string(158) "Community pharmacies that are forced to close as a result of the COVID-19 pandemic “may not open again”, the chief executive of the Pharmaceutical"
  ["short_description"]=>
  string(158) "Community pharmacies that are forced to close as a result of the COVID-19 pandemic “may not open again”, the chief executive of the Pharmaceutical"
  [3]=>
  string(201) "Community pharmacies that are forced to close as a result of the COVID-19 pandemic “may not open again”, the chief executive of the Pharmaceutical Services Negotiating Committee has warned."
  ["description"]=>
  string(201) "Community pharmacies that are forced to close as a result of the COVID-19 pandemic “may not open again”, the chief executive of the Pharmaceutical Services Negotiating Committee has warned."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(169) "https://www.pharmaceutical-journal.com/news-and-analysis/news/some-community-pharmacies-on-brink-of-collapse-following-covid-19-says-pharmacy-negotiator/20207833.article"
  ["blog_url"]=>
  string(169) "https://www.pharmaceutical-journal.com/news-and-analysis/news/some-community-pharmacies-on-brink-of-collapse-following-covid-19-says-pharmacy-negotiator/20207833.article"
  [15]=>
  string(19) "2020-03-17 00:01:00"
  ["add_date"]=>
  string(19) "2020-03-17 00:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:46"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8452"
  ["article_id"]=>
  string(4) "8452"
  [1]=>
  string(62) "Spaulding strikes 5-year agreement with FDA on clinical trials"
  ["article_title"]=>
  string(62) "Spaulding strikes 5-year agreement with FDA on clinical trials"
  [2]=>
  string(150) "Spaulding has been contracted by the US FDA to support clinical trials in various therapeutic areas for the following five years, starting with a $5m "
  ["short_description"]=>
  string(150) "Spaulding has been contracted by the US FDA to support clinical trials in various therapeutic areas for the following five years, starting with a $5m "
  [3]=>
  string(176) "Spaulding has been contracted by the US FDA to support clinical trials in various therapeutic areas for the following five years, starting with a $5m reward for the first year."
  ["description"]=>
  string(176) "Spaulding has been contracted by the US FDA to support clinical trials in various therapeutic areas for the following five years, starting with a $5m reward for the first year."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(155) "https://www.outsourcing-pharma.com/Article/2020/03/16/Spaulding-in-clinical-trial-contract-with-the-FDA?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(155) "https://www.outsourcing-pharma.com/Article/2020/03/16/Spaulding-in-clinical-trial-contract-with-the-FDA?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-16 23:40:00"
  ["add_date"]=>
  string(19) "2020-03-16 23:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:40"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8453"
  ["article_id"]=>
  string(4) "8453"
  [1]=>
  string(75) "Recruitment platform offered free-of-charge for coronavirus clinical trials"
  ["article_title"]=>
  string(75) "Recruitment platform offered free-of-charge for coronavirus clinical trials"
  [2]=>
  string(146) "Aiming to support the ongoing clinical research on coronavirus vaccines, ClinOne will be offering its patient recruitment services free-of-charge."
  ["short_description"]=>
  string(146) "Aiming to support the ongoing clinical research on coronavirus vaccines, ClinOne will be offering its patient recruitment services free-of-charge."
  [3]=>
  string(146) "Aiming to support the ongoing clinical research on coronavirus vaccines, ClinOne will be offering its patient recruitment services free-of-charge."
  ["description"]=>
  string(146) "Aiming to support the ongoing clinical research on coronavirus vaccines, ClinOne will be offering its patient recruitment services free-of-charge."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(161) "https://www.outsourcing-pharma.com/Article/2020/03/16/ClinOne-offers-free-services-to-coronavirus-researchers?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(161) "https://www.outsourcing-pharma.com/Article/2020/03/16/ClinOne-offers-free-services-to-coronavirus-researchers?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-16 23:37:00"
  ["add_date"]=>
  string(19) "2020-03-16 23:37:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:40"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8328"
  ["article_id"]=>
  string(4) "8328"
  [1]=>
  string(61) "RPS backs regulator's guidance on buying medicines online"
  ["article_title"]=>
  string(61) "RPS backs regulator's guidance on buying medicines online"
  [2]=>
  string(150) "The Royal Pharmaceutical Society is one of nine healthcare bodies backing new General Pharmaceutical Council guidance for patients ordering medicines "
  ["short_description"]=>
  string(150) "The Royal Pharmaceutical Society is one of nine healthcare bodies backing new General Pharmaceutical Council guidance for patients ordering medicines "
  [3]=>
  string(170) "The Royal Pharmaceutical Society is one of nine healthcare bodies backing new General Pharmaceutical Council guidance for patients ordering medicines or treatment online."
  ["description"]=>
  string(170) "The Royal Pharmaceutical Society is one of nine healthcare bodies backing new General Pharmaceutical Council guidance for patients ordering medicines or treatment online."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(121) "https://www.pharmaceutical-journal.com/your-rps/rps-backs-regulators-guidance-on-buying-medicines-online/20207831.article"
  ["blog_url"]=>
  string(121) "https://www.pharmaceutical-journal.com/your-rps/rps-backs-regulators-guidance-on-buying-medicines-online/20207831.article"
  [15]=>
  string(19) "2020-03-16 23:14:00"
  ["add_date"]=>
  string(19) "2020-03-16 23:14:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:46"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8440"
  ["article_id"]=>
  string(4) "8440"
  [1]=>
  string(62) "Manufacturer to avoid potential export delays following Brexit"
  ["article_title"]=>
  string(62) "Manufacturer to avoid potential export delays following Brexit"
  [2]=>
  string(123) "UK manufacturer, Broadwater Mouldings, part of the Betts Group, has been granted Authorised Economic Operator (AEO) status."
  ["short_description"]=>
  string(123) "UK manufacturer, Broadwater Mouldings, part of the Betts Group, has been granted Authorised Economic Operator (AEO) status."
  [3]=>
  string(123) "UK manufacturer, Broadwater Mouldings, part of the Betts Group, has been granted Authorised Economic Operator (AEO) status."
  ["description"]=>
  string(123) "UK manufacturer, Broadwater Mouldings, part of the Betts Group, has been granted Authorised Economic Operator (AEO) status."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/manufacturer-to-avoid-potential-export-delays-following-brex/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/manufacturer-to-avoid-potential-export-delays-following-brex/"
  [15]=>
  string(19) "2020-03-16 23:01:26"
  ["add_date"]=>
  string(19) "2020-03-16 23:01:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:35"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}